Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ therapeutic use
Cetuximab
/ therapeutic use
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Lung Neoplasms
/ drug therapy
Lymph Nodes
/ pathology
Lymphatic Metastasis
Male
Middle Aged
Nivolumab
/ therapeutic use
Progression-Free Survival
Radiotherapy
/ statistics & numerical data
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Tumor Burden
Head and neck squamous cell carcinoma
Nivolumab
Predictive factor
Tumor size
Journal
Auris, nasus, larynx
ISSN: 1879-1476
Titre abrégé: Auris Nasus Larynx
Pays: Netherlands
ID NLM: 7708170
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
26
10
2019
revised:
18
12
2019
accepted:
17
01
2020
pubmed:
10
2
2020
medline:
15
7
2021
entrez:
10
2
2020
Statut:
ppublish
Résumé
Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab. We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions. In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: -10.0% vs. 23.1%, p = 0.033). PTS may impact the response to nivolumab in HNSCC patients.
Identifiants
pubmed: 32035695
pii: S0385-8146(20)30023-7
doi: 10.1016/j.anl.2020.01.003
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immune Checkpoint Inhibitors
0
Nivolumab
31YO63LBSN
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
650-657Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Tomoya Yokota serves in an advisory role at Merck Serono and AstraZeneca and Bristol-Myers Squibb, has received lecture fees from Merck Serono.